XORTX Therapeutics Inc XRTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:51 PM EDT
2.68quote price arrow up+0.08 (+3.01%)
Volume
3,482
52 week range
1.98 - 7.52
Loading...
  • Open2.55
  • Day High2.85
  • Day Low2.55
  • Prev Close2.60
  • 52 Week High7.52
  • 52 Week High Date10/20/23
  • 52 Week Low1.98
  • 52 Week Low Date12/27/23

Key Stats

  • Market Cap5.96M
  • Shares Out2M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change15.89

KEY STATS

  • Open2.55
  • Day High2.85
  • Day Low2.55
  • Prev Close2.60
  • 52 Week High7.52
  • 52 Week High Date10/20/23
  • 52 Week Low1.98
  • 52 Week Low Date12/27/23
  • Market Cap5.96M
  • Shares Out2M
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change15.89

RATIOS/PROFITABILITY

  • EPS (TTM)-1.11
  • P/E (TTM)-2.41
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/15/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On XORTX Therapeutics Inc

 

Profile

MORE
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and...
Anthony Giovinazzo
Independent Non-Executive Chairman of the Board
Allen Davidoff Ph.D.
President, Chief Executive Officer, Director
James Fairbairn CPA
Chief Financial Officer
Address
3710 - 33rd Street NW
Calgary, AB
T2L 2M1
Canada